profit from every $100 of sales.
$0$100
Artiva Biotherapeutics
$4.01+1.26% today
+18.3% in 1 year
1-year low $3.071-year high $13.39
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2024.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Artiva Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $4.93 million in 2022 to $0 in 2025, with -$83.9 million of profit last year.
SalesProfit
Artiva Biotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Artiva Biotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Artiva Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 5 | 33 | 0 | 0 | |
| – | – | – | – | |
| -60 | -31 | -67 | -90 | |
| -59 | -28 | -65 | -87 | |
| -61 | -33 | -58 | -84 | |
| -6.51 | -1.41 | -5.81 | -3.43 | |
| – | – | – | – | |
| -1,213.3% | -91.6% | -26,805.6% | – | |
| -1,236.6% | -97.8% | -23,178.9% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 133 | 105 | 210 | 131 |
| Cash | 103 | 54 | 40 | 27 |
| Total debt | 19 | 17 | 14 | 11 |
| Total liabilities | 274 | 267 | 23 | 21 |
| -141 | -162 | 187 | 110 | |
| 9 | 23 | 11 | 24 | |
| – | – | -26.4% | -58.7% | |
| 43.3% | 20.2% | -31.2% | -76.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -51 | -47 | -55 | -77 | |
| 6 | 3 | 1 | 3 | |
| -57 | -51 | -56 | -79 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 4 | 0 | |
| 7 | 7 | 7 | 7 |
Valuation
- –
- –
- –
- 3.1×
- 789.7×
- –
- –
- -28.1%
- -29.4%
- 0.0%
Profitability
- 0.0%
- -26,805.6%
- -23,178.9%
- 0.0%
- -94.7%
- 10.2%
- -73.2%
- -82.2%
- -97.7%
- –
Growth
- −77.4%
- –
- −42.5%
- –
- +8.6%
Financial health
- -0.4×
- 0.12
- 9.7%
- –
- 8.16
- 8.16
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 946
Bottom 1%of 867
Bottom 2%of 986
What analysts expect
- Average price target
- $20.50
- Range
- $18.00 – $23.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | -0.95 | -0.88 | −8.0% |
| Mar 10, 2026 | -0.84 | -0.87 | +3.4% |
| Nov 12, 2025 | -0.88 | -0.92 | +4.3% |
| Aug 6, 2025 | -0.87 | -0.84 | −3.6% |
| May 8, 2025 | -0.83 | -0.68 | −22.1% |
| Mar 25, 2025 | -0.66 | -0.71 | +7.0% |
| Nov 12, 2024 | -0.92 | -0.68 | −35.3% |
| Aug 29, 2024 | -22.00 | -4.40 | −400.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
39No pass
Philip Fisher
38No pass
Peter Lynch
12No pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
30No pass
Questions about Artiva Biotherapeutics
Is Artiva Biotherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Artiva Biotherapeutics AI analysis
What does Artiva Biotherapeutics do?
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. It is in Biotechnology.
Does Artiva Biotherapeutics pay a dividend?
No. Artiva Biotherapeutics does not pay a dividend at the moment.
Is Artiva Biotherapeutics stock halal?
Questionable. Artiva Biotherapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Artiva Biotherapeutics stock done over the past year?
Up 18.3% over the past twelve months, to $4.01. It traded between $3.07 and $13.39 and is 70.1% below its high.
Who are Artiva Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Artiva Biotherapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.